based in South San Francisco, California, Onyx Pharmaceuticals is an Amgen subsidiary, engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.
Innovation: We are expanding innovation beyond science to focus on rethinking each aspect of the way we serve patients.
Patient-Centeredness: We are here for patients, and everything we do is in service of them and their families who are waiting for breakthrough therapies and innovative approaches to treating their diseases.
Stewardship: We are thoughtful in how we plan for and manage our resources, partnerships and people, including our financial and operational discipline, how we engage with and attract strategic partners, how we govern ourselves, in our commitment to corporate citizenship by supporting the communities in which we serve, and in the development of our employees into leaders.
Onyx is committed to helping patients gain appropriate access to our medicines.
The Resources for Expert Assistance and Care Helpline (REACH®) is available to answer questions about Nexavar treatment, reimbursement, and patient support. For more information, healthcare providers and patients may contact the REACH program at 1.866.NEXAVAR (1.866.639.2827) Monday through Friday from 9:00 a.m. to 8:00 a.m. ET.
Onyx Pharmaceuticals 360™ (Onyx 360) is a program designed to help patients navigate their treatment journey, including reimbursement and payment support, treatment support and referrals to third-party organizations for day-to-day and emotional support. Dedicated Oncology Nurse Advocates are available Monday through Friday from 9:00 a.m. to 8:00 p.m. Eastern Standard Time at 1-855-ONYX-360 (1-855-669-9360) to assist patients, caregivers and healthcare providers.
Onyx has more than 900 employees in the United States and Europe, and is growing.